We are working on the following new projects:

• We were awarded with two contracts for full-service support in bioequivalence trials with Rivaroxaban 10 mg and 20 mg.
• Smooth signed a contract for a synopsis development with Rabeprazole.
• A contract for medical writing services was signed with Mebeverine.

We are happy to reach the following milestones in our projects:

• The clinical part was completed in the Rivaroxaban, 10 mg and Gabapentin trials.
• The site was initiated in the Rivaroxaban, 20 mg and the Rivaroxaban, 2,5 mg trial.
• The last site was closed in the Azacitidine trial.